Iasocholine (Fluorocholine (18f) Chloride)

Fluorocholine (18F) Chloride mimics natural choline and is taken up by cells via choline transporters. Inside the cell, it is phosphorylated by choline kinase and incorporated into phosphatidylcholine, a membrane component. Tumor and hyperactive cells have increased choline kinase activity, leading to higher tracer accumulation that PET scanners detect as bright signals.

The administered activity of Iasocholine is determined by the prescribing physician or nuclear medicine specialist based on patient weight, the specific imaging protocol, and regulatory guidelines. Dosage is individualized and should be prepared by qualified radiopharmacy personnel according to local and international standards.

Fluorocholine (18F) Chloride involves exposure to ionizing radiation, which may pose risks to a developing fetus or nursing infant. It is generally avoided in pregnant or breastfeeding patients unless the diagnostic benefit is deemed essential and no alternative is available. Consultation with a radiology and obstetrics specialist is recommended.

To request Iasocholine, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Compared with ^18F‑FDG, a glucose‑based tracer, Fluorocholine targets choline metabolism, offering higher specificity for certain prostate cancers and neuro‑oncologic lesions that may show low FDG uptake. It provides complementary information, especially in cases where FDG results are equivocal, but its use is limited to indications where choline metabolism is a known marker.

Iasocholine must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original sealed container. It should not be frozen or shaken, and any vial that has been out of the recommended temperature range for more than 30 minutes should be discarded to maintain tracer integrity.

Iasocholine is administered intravenously as a sterile injectable solution. The prepared dose is injected over a short period, typically a few seconds, followed by a waiting interval (usually 10‑20 minutes) before PET imaging begins to allow optimal tissue uptake and background clearance.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension immediately after injection, and rare radiation‑induced skin injury at the injection site. Prompt recognition and management of these events are essential, and facilities should have emergency equipment and trained personnel available.

Iasocholine should be avoided in patients with known hypersensitivity to choline‑based compounds, those with uncontrolled severe hypertension or cardiac instability, pregnant or breastfeeding women unless absolutely necessary, and individuals who have received other radiopharmaceuticals with overlapping emission spectra within a short timeframe.